Analysts predict that GW Pharmaceuticals PLC- (NASDAQ:GWPH) will post ($0.66) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for GW Pharmaceuticals PLC-‘s earnings. The lowest EPS estimate is ($1.56) and the highest is ($0.36). GW Pharmaceuticals PLC- reported earnings per share of ($2.35) in the same quarter last year, which suggests a positive year-over-year growth rate of 71.9%. The business is expected to report its next quarterly earnings results on Tuesday, February 25th.
According to Zacks, analysts expect that GW Pharmaceuticals PLC- will report full-year earnings of ($0.15) per share for the current financial year, with EPS estimates ranging from ($1.08) to $0.24. For the next fiscal year, analysts anticipate that the company will post earnings of $1.68 per share, with EPS estimates ranging from ($0.60) to $9.00. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that follow GW Pharmaceuticals PLC-.
GWPH has been the topic of a number of analyst reports. Morgan Stanley boosted their price objective on shares of GW Pharmaceuticals PLC- to $238.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Oppenheimer cut their target price on GW Pharmaceuticals PLC- to $222.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Bank of America reissued a “buy” rating and issued a $218.00 price target on shares of GW Pharmaceuticals PLC- in a report on Wednesday, September 25th. Evercore ISI reissued a “buy” rating on shares of GW Pharmaceuticals PLC- in a report on Monday, November 11th. Finally, Zacks Investment Research downgraded GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a report on Friday, November 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have assigned a buy rating to the company. GW Pharmaceuticals PLC- has an average rating of “Buy” and an average target price of $199.18.
Hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC increased its holdings in GW Pharmaceuticals PLC- by 25,456.4% in the 1st quarter. FMR LLC now owns 134,682 shares of the biopharmaceutical company’s stock valued at $22,704,000 after buying an additional 134,155 shares during the period. NEXT Financial Group Inc raised its holdings in shares of GW Pharmaceuticals PLC- by 270.6% in the 2nd quarter. NEXT Financial Group Inc now owns 567 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 414 shares in the last quarter. BB&T Corp raised its holdings in shares of GW Pharmaceuticals PLC- by 19.7% in the 2nd quarter. BB&T Corp now owns 1,817 shares of the biopharmaceutical company’s stock valued at $313,000 after purchasing an additional 299 shares in the last quarter. Westside Investment Management Inc. purchased a new stake in shares of GW Pharmaceuticals PLC- in the 2nd quarter worth approximately $42,000. Finally, Brookstone Capital Management purchased a new stake in shares of GW Pharmaceuticals PLC- in the 2nd quarter worth approximately $210,000. 81.11% of the stock is owned by institutional investors.
GWPH traded down $2.22 during trading on Thursday, reaching $103.69. The company had a trading volume of 18,047 shares, compared to its average volume of 531,161. The company has a quick ratio of 6.60, a current ratio of 7.33 and a debt-to-equity ratio of 0.03. The business has a 50 day simple moving average of $115.46 and a 200-day simple moving average of $145.63. The stock has a market cap of $3.27 billion, a P/E ratio of -9.86 and a beta of 2.17. GW Pharmaceuticals PLC- has a 52 week low of $90.14 and a 52 week high of $196.00.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Further Reading: What are the benefits of momentum investing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.